Columbia neuroscientists have identified a genetic mutation that fends off Alzheimer's in people at high risk and could lead to a new way to protect people from the disease.
ADScreen, a speech-processing algorithm developed at Columbia Nursing, is now being tested in a clinical trial to see if it can help health care workers identify patients with Alzheimer's earlier.
Lecanemab, marketed as Leqembi, is the first drug for Alzheimer’s disease to receive approval on the basis of clinically slowing the progression of Alzheimer’s disease.
Attending a high school with a high number of teachers with graduate training was the clearest predictor of the impact of school quality on late-life cognition, researchers found.
A Columbia-led research team has clinically validated a new method for predicting time to nursing home residence or death for patients with Alzheimer’s.
Deficiency of a protein in the hippocampus is a major cause of age-related memory loss, and this form of memory loss is reversible, according to Columbia researchers.
Ottavio Arancio, MD, PhD, of CUMC's Taub Institute, coauthored a paper on a compound that prevents memory loss in a mouse model of Alzheimer's. See Northwestern's news release: http://bit.ly/14Zqwwn
Columbia University study looks at the relationship between families with exceptional longevity and cognitive impairment consistent with Alzheimer's disease.
African-Americans carrying a variant in a cholesterol-processing gene, ABCA7, have double the risk for Alzheimer’s than non-carriers. A new study led by CUMC's Richard Mayeux; first author Christiane Reitz.
African-Americans with Alzheimer’s disease were slightly more likely to have one gene, ABCA7, that is thought to confer risk for the disease. CUMC's Dr. Richard Mayeux led the study.
The largest genome-wide search for Alzheimer’s genes in African-Americans has found that African-Americans with a variant of the ABCA7 gene have almost double the risk of developing late-onset Alzheimer’s disease.